Clinician reference tool — not medical advice. This is a clinical decision-aid intended for healthcare professionals: it gives deterministic suggestions to think with, not a diagnosis or a prescription. If you’re a patient, you’re welcome to look around — but please review anything here with your own doctor; it isn’t a substitute for personalized medical care.
← TestSelect

Comprehensive digestive stool analysis / microbiome profile

GI / immune · specimen: stool

No validated clinical use

Also called: comprehensive stool analysis, CDSA, GI-MAP, GI Effects, stool microbiome test, gut microbiome test, digestive stool analysis, comprehensive digestive stool analysis, microbiome profile stool test

Chart note

ND-recommended test reviewed: comprehensive digestive stool analysis / microbiome profile.
Indications reviewed: bloating, irregular bowel habits, fatigue, suspected dysbiosis; red flags absent.
Not ordered. Rationale discussed: no consensus on regulation or proven clinical value for commercial microbiome panels. Ref: Porcari et al 2024 international consensus statement.
Patient informed test available privately via ND. Patient given info page: https://labs.ajaxharwoodclinic.com/comprehensive-stool-analysis/patient
Revisit if: red-flag features develop (weight loss, GI bleeding, iron-deficiency anemia, nocturnal symptoms, new onset age 50 or over).

Indicated when

None recorded.

Not indicated when

  • Ordering a commercial comprehensive stool analysis or gut microbiome profile (e.g. GI-MAP, GI Effects, or similar branded panels) to diagnose 'dysbiosis', guide supplement or diet choices, or explain fatigue, bloating, or other nonspecific GI symptoms, in any patient [1]
  • Using a commercial microbiome panel in place of red-flag GI workup (e.g. colonoscopy, standard stool culture, celiac serology) when alarm features (weight loss, GI bleeding, iron-deficiency anemia, nocturnal symptoms, family history of IBD/colorectal cancer/celiac, new onset at age 50 or over) are present

Why not

An international multidisciplinary expert panel found that commercial microbiome diagnostic tests are offered directly to consumers 'without any consensus on their regulation or any proven value in clinical practice,' which the panel warned 'could result in considerable waste of individual and health-care resources' [1]. There is no validated reference range for a healthy microbiome, and results are not established as reproducible enough between commercial labs, specimens, or days to safely guide a treatment decision. Acting on a report can lead to costly supplement regimens and unnecessarily restrictive diets.

Better first step

Name and investigate the actual condition behind the symptoms (for example IBS by Rome criteria, IBD, celiac disease, or post-infectious changes) using validated tests such as celiac serology, fecal calprotectin when IBD is a concern, or a standard diagnostic stool culture (L630, insured) for suspected bacterial infection, rather than a commercial microbiome panel.

Typical ND rationale

An ND may order a comprehensive stool analysis in a patient with bloating, irregular bowel habits, or fatigue, reasoning that an imbalance in gut bacteria (dysbiosis) could be an underlying driver of symptoms, and that a detailed stool panel can identify which organisms or digestive markers to target.

Where the ND is right

The idea that gut microbial balance affects health, and that persistent GI symptoms deserve real investigation rather than dismissal, is a legitimate and active area of research. No validated situation was identified, however, in which a commercial comprehensive stool/microbiome panel changes management for an individual patient; the international consensus statement explicitly frames the field as promising but not yet ready for that clinical use [1].

Ontario coverage & CONO orderability

OHIP status
unverified
'Comprehensive Digestive Stool Analysis' and the underlying bacteria/yeast microbiology profile (CONO 134, 136) do not appear by name in the 2026 Schedule of Benefits for Laboratory Services (searched in full), so billing status if a physician ordered one is unverified. A standard diagnostic stool culture for enteric pathogens (L630, fee $17.37) is separately listed and insured when physician-ordered; it is a different, validated test, not the commercial microbiome panel. ND-ordered testing is privately paid regardless (Reg. 552 s.22(1)).
CONO orderable
Yes — CONO list #134, #136
CONO 134 'Bacteria / yeast (microbiology profile)' and CONO 136 'Comprehensive Digestive Stool Analysis', both stool specimen, cover the branded commercial panels (e.g. GI-MAP, GI Effects).

Linked conditions

Counselling script

“I understand wanting a clearer picture of what's going on in your gut, but this stool microbiome panel isn't something international gut specialists consider ready for guiding treatment yet, since there's no agreed normal pattern and no proof it changes outcomes. What I'd rather do is check for the specific things that actually explain your symptoms, like celiac disease or inflammation, which gives us a result we can act on.”

Revisit if

  • Weight loss, GI bleeding, iron-deficiency anemia, nocturnal symptoms, or new onset at age 50 or over
  • Family history of inflammatory bowel disease, colorectal cancer, or celiac disease
  • Symptoms persist despite reassurance and a structured first-line work-up

References

  1. [1]International multidisciplinary expert panel (Porcari et al.) (2024). International consensus statement on microbiome testing in clinical practice. linkInternational consensus panel: commercial microbiome diagnostics are offered without regulatory consensus or proven clinical value, risking wasted resources
  2. [2]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkCommunity lab tests are insured only when ordered under the Schedule by an authorized prescriber
  3. [3]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkStandard diagnostic stool culture (L630) is listed by name and insured, distinct from commercial microbiome panels
  4. [4]Government of Ontario (e-Laws) (2026). Health Insurance Act, R.R.O. 1990, Reg. 552: General, s. 22 (insured laboratory services). linkInsured lab testing requires ordering by an authorized provider who has clinically assessed the patient
  5. [5]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkTests ordered by anyone other than an authorized provider, including NDs, are not insured services
Evidence notes

The existing ahc-dysbiosis tool's own clinical logic (lib/classes.ts, 'avoid-microbiome-tests') independently reaches the same conclusion ('not clinically validated ... not actionable') and was reviewed to confirm consistency of tone and conclusion; it is this project's own downstream content, not cited here as an independent source. 'Dysbiosis' itself is addressed on the existing ahc-dysbiosis tool, which this record links to; no separate 'IBD vs IBS' condition id exists yet in the current condition-id list for a more targeted link.